New scan could predict lung cancer drug success
NCT ID NCT07151898
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a special PET scan using a tracer called 68Ga-MY6349 can predict how well a targeted therapy (Trop2-ADC) works in people with advanced non-small cell lung cancer (NSCLC). Fifty adult patients will receive the scan before and during treatment. The goal is to see if changes in the scan can forecast treatment success or failure, potentially guiding future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-MY6349 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a non-invasive way to predict which lung cancer patients will benefit from Trop2-ADC therapy, helping personalize treatment.
What could go wrong
This is an early-stage imaging study with only 50 participants, so results may not apply to all patients. The scan's ability to predict treatment response is still unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••